Free Trial
→ Altucher: Turn $900 into $108,000 in just 12 months? (From Paradigm Press) (Ad) Buy NEO Stock  Free NEO Stock Alerts

NeoGenomics (NEO) Financials

NeoGenomics logo
$7.84 +0.14 (+1.82%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$7.79 -0.05 (-0.59%)
As of 05:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for NeoGenomics

Annual Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 1.13 -2.66 -31 -11 6.09 8.01 4.17 -8.35 -144 -88 -79
Consolidated Net Income / (Loss)		 1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Net Income / (Loss) Continuing Operations		 1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Total Pre-Tax Income 		1.29 -4.49 -7.84 -2.65 3.82 3.65 -14 -15 -159 -97 -81
Total Operating Income		 2.22 -5.64 2.16 2.90 10 13 -14 -119 -158 -108 -92
Total Gross Profit		 41 44 98 102 127 197 186 187 188 245 290
Total Revenue		 87 100 232 240 277 409 444 484 510 592 661
Operating Revenue		 87 100 232 240 277 409 444 484 510 592 661
Total Cost of Revenue		 46 56 134 138 149 212 259 297 322 347 370
Operating Cost of Revenue		 46 56 134 138 149 212 259 297 322 347 370
Total Operating Expenses		 38 49 96 99 117 184 200 306 346 352 382
Selling, General & Admin Expense		 24 34 64 70 85 128 144 221 243 243 260
Marketing Expense		 12 12 24 24 29 47 48 63 67 71 85
Research & Development Expense		 2.69 4.20 4.65 3.64 3.00 8.49 8.23 22 30 27 31
Restructuring Charge		 - - - - - - 0.00 0.00 4.52 11 6.66
Total Other Income / (Expense), net		 -0.93 1.15 -10.00 -5.55 -6.22 -9.36 -0.06 104 -1.72 11 11
Interest Expense		 0.99 0.85 10.00 5.54 6.23 4.73 12 8.22 7.58 6.91 6.62
Interest & Investment Income		 - - - - - - - 3.14 6.08 17 18
Other Income / (Expense), net		 0.06 2.00 0.00 -0.01 0.01 -4.63 12 109 -0.21 0.64 -0.38
Income Tax Expense		 0.16 -1.95 -1.70 -2.25 1.18 -4.36 -18 -6.73 -15 -9.13 -1.95
Basic Earnings per Share		 $0.02 ($0.04) ($0.40) ($0.14) $0.07 $0.08 - - ($1.16) ($0.70) ($0.62)
Weighted Average Basic Shares Outstanding		 53.48M 60.53M 77.54M 79.43M 85.62M 100.47M 108.58M 119.96M 124.22M 125.50M 126.66M
Diluted Earnings per Share		 $0.02 ($0.04) ($0.40) ($0.14) $0.07 $0.08 - - ($1.16) ($0.70) ($0.62)
Weighted Average Diluted Shares Outstanding		 56.02M 60.53M 77.54M 79.43M 91.57M 103.62M 111.79M 119.96M 124.22M 125.50M 126.66M
Weighted Average Basic & Diluted Shares Outstanding		 56.60M 66.40M 78.82M 80.51M 94.57M 104.83M 116.94M 124.03M 127.46M 127.61M 128.46M

Quarterly Income Statements for NeoGenomics

This table shows NeoGenomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -37 -23 -31 -24 -19 -14 -27 -19 -18 -15 -26
Consolidated Net Income / (Loss)		 -37 -23 -31 -24 -19 -14 -27 -19 -18 -15 -26
Net Income / (Loss) Continuing Operations		 -37 -23 -31 -24 -19 -14 -27 -19 -18 -15 -26
Total Pre-Tax Income 		-40 -26 -34 -27 -21 -15 -28 -19 -18 -16 -26
Total Operating Income		 -40 -26 -35 -30 -24 -19 -31 -22 -21 -18 -28
Total Gross Profit		 49 57 55 60 62 68 65 72 75 77 73
Total Revenue		 129 139 137 147 152 156 156 165 168 172 168
Operating Revenue		 129 139 137 147 152 156 156 165 168 172 168
Total Cost of Revenue		 80 82 82 87 90 88 91 92 93 95 95
Operating Cost of Revenue		 80 82 82 87 90 88 91 92 93 95 95
Total Operating Expenses		 88 83 90 90 87 86 96 94 96 96 101
Selling, General & Admin Expense		 64 55 62 60 61 60 66 63 67 64 68
Marketing Expense		 17 17 16 19 18 18 20 22 20 22 23
Research & Development Expense		 7.31 6.68 7.40 7.50 5.29 7.13 7.62 7.89 7.68 7.97 10
Restructuring Charge		 0.00 4.52 4.68 3.07 2.13 1.21 2.40 1.54 1.01 1.71 0.00
Total Other Income / (Expense), net		 -0.11 0.86 1.35 3.25 2.74 3.29 2.89 2.92 3.35 2.27 2.17
Interest Expense		 0.14 5.22 1.76 1.78 1.69 1.68 1.69 1.67 1.64 1.62 1.62
Interest & Investment Income		 - - 3.22 4.31 4.53 4.85 4.83 4.59 4.67 4.33 3.72
Other Income / (Expense), net		 0.03 -0.00 -0.11 0.73 -0.10 0.12 -0.26 -0.00 0.32 -0.43 0.07
Income Tax Expense		 -2.77 -2.84 -2.93 -2.31 -2.94 -0.96 -0.62 -0.38 -0.15 -0.80 0.27
Basic Earnings per Share		 ($0.30) ($0.18) ($0.25) - ($0.15) - ($0.21) - ($0.14) - ($0.20)
Weighted Average Basic Shares Outstanding		 124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M 127.38M
Diluted Earnings per Share		 ($0.30) ($0.18) ($0.25) - ($0.15) - ($0.21) - ($0.14) - ($0.20)
Weighted Average Diluted Shares Outstanding		 124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M 127.38M
Weighted Average Basic & Diluted Shares Outstanding		 126.30M 127.46M 127.58M 127.55M 127.47M 127.61M 127.71M 128.16M 128.36M 128.46M 128.69M

Annual Cash Flow Statements for NeoGenomics

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 29 -10 -11 0.30 -3.01 163 78 66 -54 79 25
Net Cash From Operating Activities		 9.45 6.39 21 18 45 23 1.46 -27 -66 -1.95 7.02
Net Cash From Continuing Operating Activities		 9.45 6.39 21 18 45 23 1.46 -27 -66 -1.95 7.02
Net Income / (Loss) Continuing Operations		 1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Consolidated Net Income / (Loss)		 1.13 -2.54 -6.14 -0.40 2.64 8.01 4.17 -8.35 -144 -88 -79
Depreciation Expense		 5.35 6.73 16 16 16 20 26 30 35 37 39
Amortization Expense		 0.36 0.41 11 7.44 6.47 10 14 26 37 38 36
Non-Cash Adjustments To Reconcile Net Income		 3.13 3.73 10 7.75 7.36 17 -6.35 -84 36 28 37
Changes in Operating Assets and Liabilities, net		 -0.52 -1.95 -9.09 -12 13 -32 -37 10 -30 -18 -26
Net Cash From Investing Activities		 -9.60 -75 -6.50 -14 -140 -20 -159 -632 0.52 77 13
Net Cash From Continuing Investing Activities		 -9.60 -75 -6.50 -14 -140 -20 -159 -632 0.52 77 13
Purchase of Property, Plant & Equipment		 -3.77 -2.22 -7.54 -14 -14 -20 -29 -64 -31 -29 -41
Purchase of Investments		 - - - - 0.00 0.00 -99 -212 -98 -6.76 0.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.00 12 0.00 0.00
Sale and/or Maturity of Investments		 - - - - 0.00 0.00 5.36 63 117 112 54
Net Cash From Financing Activities		 29 58 -26 -4.10 92 159 236 725 12 4.55 4.65
Net Cash From Continuing Financing Activities		 29 58 -26 -4.10 92 159 236 725 12 4.55 4.65
Issuance of Common Equity		 37 0.94 3.77 2.59 9.02 11 20 15 13 4.62 4.65
Other Financing Activities, net		 - - - -5.42 -6.56 -7.20 -8.93 -32 -0.76 -0.07 0.00
Cash Interest Paid		 0.98 0.91 5.42 5.16 6.51 4.78 2.93 3.07 3.40 3.38 3.83
Cash Income Taxes Paid		 0.18 0.03 0.29 0.28 -0.03 0.32 0.25 0.15 0.18 0.18 0.21

Quarterly Cash Flow Statements for NeoGenomics

This table details how cash moves in and out of NeoGenomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -18 -2.95 12 13 17 36 -11 23 6.91 5.02 -21
Net Cash From Operating Activities		 -16 -3.69 -13 -1.55 -5.50 18 -26 14 9.25 9.80 -25
Net Cash From Continuing Operating Activities		 -16 -3.69 -13 -1.55 -5.50 18 -26 14 9.25 9.80 -25
Net Income / (Loss) Continuing Operations		 -37 -23 -31 -24 -19 -14 -27 -19 -18 -15 -26
Consolidated Net Income / (Loss)		 -37 -23 -31 -24 -19 -14 -27 -19 -18 -15 -26
Depreciation Expense		 8.97 9.48 9.05 9.48 9.35 9.58 9.91 9.75 9.62 9.83 9.37
Amortization Expense		 9.20 9.30 9.50 9.50 9.51 9.51 9.09 9.09 9.09 9.09 9.10
Non-Cash Adjustments To Reconcile Net Income		 7.58 15 6.29 7.19 13 1.70 8.89 13 6.48 8.53 11
Changes in Operating Assets and Liabilities, net		 -5.17 -14 -6.73 -3.38 -19 11 -27 0.85 1.76 -2.32 -29
Net Cash From Investing Activities		 -4.20 -1.06 24 15 21 17 15 7.31 -3.52 -5.47 3.56
Net Cash From Continuing Investing Activities		 -4.20 -1.06 24 15 21 17 15 7.31 -3.52 -5.47 3.56
Purchase of Property, Plant & Equipment		 -7.84 -4.53 -9.93 -7.49 -4.27 -7.06 -5.59 -13 -11 -12 -4.50
Sale and/or Maturity of Investments		 21 27 40 22 25 24 20 20 7.28 6.13 8.06
Net Cash From Financing Activities		 2.96 1.80 1.38 0.06 1.84 1.27 0.82 1.97 1.18 0.69 0.95
Net Cash From Continuing Financing Activities		 2.96 1.80 1.38 0.06 1.84 1.27 0.82 1.97 1.18 0.69 0.95
Issuance of Common Equity		 3.09 1.85 1.41 0.09 1.85 1.27 0.82 1.97 1.18 0.69 0.95
Cash Interest Paid		 0.00 1.26 0.43 1.26 0.43 1.26 0.43 1.26 0.45 1.69 0.00
Cash Income Taxes Paid		 0.03 0.03 0.00 0.18 - - 0.09 0.09 0.14 -0.11 0.00

Annual Balance Sheets for NeoGenomics

This table presents NeoGenomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 81 351 337 344 505 710 988 1,870 1,740 1,681 1,638
Total Current Assets		 59 82 79 86 104 291 449 682 605 597 596
Cash & Equivalents		 34 23 13 13 9.81 173 229 317 263 342 367
Short-Term Investments		 - - - - - 0.00 68 - 175 73 20
Accounts Receivable		 20 49 56 60 77 94 107 112 120 131 151
Inventories, net		 2.62 5.11 6.25 7.47 8.65 14 30 23 24 24 27
Prepaid Expenses		 1.14 4.89 4.54 4.15 7.73 6.33 12 12 15 18 20
Other Current Assets		 - - - 1.00 0.56 2.75 4.56 18 8.08 8.24 12
Plant, Property, & Equipment, net		 15 35 34 37 61 64 86 109 102 92 94
Total Noncurrent Assets		 7.28 234 224 222 340 355 454 1,079 1,032 992 948
Goodwill		 2.93 146 147 147 198 199 211 527 523 523 523
Intangible Assets		 4.21 88 77 74 140 127 121 442 408 373 340
Other Noncurrent Operating Assets		 0.14 0.13 0.17 0.89 2.54 29 92 109 101 97 85
Total Liabilities & Shareholders' Equity		 81 351 337 344 505 710 988 1,870 1,740 1,681 1,638
Total Liabilities		 21 113 151 140 185 202 294 762 742 740 736
Total Current Liabilities		 15 40 38 36 61 64 73 87 90 96 301
Short-Term Debt		 3.22 14 8.73 8.99 7.87 5.00 - - - 0.00 201
Accounts Payable		 6.29 12 17 10 18 20 25 18 21 20 22
Accrued Expenses		 1.21 7.37 4.25 6.14 8.99 7.55 12 18 15 15 13
Current Deferred Revenue		 - - - - - 1.61 4.03 5.19 7.56 2.13 0.41
Current Employee Benefit Liabilities		 3.90 6.22 8.35 9.48 19 21 25 38 40 53 62
Other Current Liabilities		 0.00 - - 1.41 7.23 8.81 7.81 8.02 6.65 5.61 3.38
Total Noncurrent Liabilities		 6.08 73 112 103 124 138 221 674 652 643 434
Long-Term Debt		 0.06 52 92 91 98 92 168 532 535 538 340
Noncurrent Deferred & Payable Income Tax Liabilities		 0.82 16 15 6.69 22 16 5.42 55 35 24 22
Other Noncurrent Operating Liabilities		 - - - 0.28 3.06 31 47 86 82 81 73
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 60 210 164 172 320 507 694 1,108 998 942 902
Total Preferred & Common Equity		 60 210 164 172 320 507 694 1,108 998 942 902
Total Common Equity		 60 210 164 172 320 507 694 1,108 998 942 902
Common Stock		 80 232 216 230 340 520 701 1,124 1,161 1,190 1,228
Retained Earnings		 -19 -22 -52 -58 -19 -11 -7.19 -15 -159 -247 -326
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.27 -0.58 -1.62 0.01 -0.64 -3.90 -1.67 -0.21

Quarterly Balance Sheets for NeoGenomics

This table presents NeoGenomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 1,756 1,709 1,695 1,678 1,640 1,643 1,641 1,601
Total Current Assets		 603 585 585 587 574 584 590 574
Cash & Equivalents		 266 276 289 306 332 355 362 346
Short-Term Investments		 177 142 120 96 53 33 26 12
Accounts Receivable		 112 119 125 133 140 147 151 151
Inventories, net		 24 24 25 24 20 23 24 30
Prepaid Expenses		 17 16 17 19 19 17 18 23
Other Current Assets		 7.52 7.62 8.43 9.32 9.31 9.16 8.31 12
Plant, Property, & Equipment, net		 107 103 100 95 88 92 93 90
Total Noncurrent Assets		 1,045 1,021 1,010 997 979 967 958 938
Goodwill		 523 523 523 523 523 523 523 523
Intangible Assets		 417 399 391 382 365 356 348 331
Other Noncurrent Operating Assets		 106 99 97 92 91 88 87 84
Total Liabilities & Shareholders' Equity		 1,756 1,709 1,695 1,678 1,640 1,643 1,641 1,601
Total Liabilities		 743 735 739 731 717 727 733 713
Total Current Liabilities		 85 87 95 93 77 290 296 280
Short-Term Debt		 - - - - - 200 200 201
Accounts Payable		 14 23 18 17 18 17 17 16
Accrued Expenses		 20 18 18 19 18 17 23 19
Current Deferred Revenue		 6.39 6.07 5.71 3.62 1.14 0.97 0.59 1.16
Current Employee Benefit Liabilities		 38 33 46 48 35 51 52 39
Other Current Liabilities		 6.50 6.97 7.37 6.22 4.49 3.57 3.72 3.08
Total Noncurrent Liabilities		 658 648 644 638 640 437 436 433
Long-Term Debt		 535 536 537 537 539 340 340 341
Noncurrent Deferred & Payable Income Tax Liabilities		 38 32 29 25 23 23 23 21
Other Noncurrent Operating Liabilities		 85 80 79 75 78 75 74 72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,013 974 956 947 923 916 908 888
Total Preferred & Common Equity		 1,013 974 956 947 923 916 908 888
Total Common Equity		 1,013 974 956 947 923 916 908 888
Common Stock		 1,154 1,167 1,173 1,182 1,199 1,210 1,219 1,240
Retained Earnings		 -136 -190 -214 -233 -274 -293 -310 -352
Accumulated Other Comprehensive Income / (Loss)		 -5.10 -2.83 -2.57 -1.85 -1.33 -1.02 -0.64 -0.06

Annual Metrics and Ratios for NeoGenomics

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 31.00% 14.62% 132.27% 3.64% 15.19% 47.73% 8.71% 8.97% 5.24% 16.07% 11.65%
EBITDA Growth		 4.52% -56.05% 722.95% -10.19% 24.72% 20.75% -2.37% 20.96% -285.61% 63.03% 46.18%
EBIT Growth		 -28.36% -259.85% 159.28% 34.11% 247.89% -16.69% -125.44% -368.93% -1,479.47% 32.15% 13.64%
NOPAT Growth		 -34.04% -302.51% 138.24% 34.66% 241.21% 312.14% -134.29% -748.73% -32.73% 31.65% 14.51%
Net Income Growth		 -44.32% -323.94% -142.29% 93.55% 766.67% 203.26% -47.89% -300.07% -1,628.17% 39.02% 10.51%
EPS Growth		 -50.00% -300.00% -900.00% 65.00% 150.00% 14.29% 0.00% 0.00% 0.00% 39.66% 11.43%
Operating Cash Flow Growth		 324.34% -32.35% 235.95% -16.02% 148.30% -47.82% -93.75% -1,930.34% -146.95% 97.04% 459.60%
Free Cash Flow Firm Growth		 -89.55% -4,139.80% 102.88% -303.13% -654.76% 112.42% -923.80% -483.38% 88.05% 44.48% -26.82%
Invested Capital Growth		 29.22% 712.77% -2.04% 6.04% 40.20% 3.50% 24.44% 109.72% -2.67% -2.81% -0.74%
Revenue Q/Q Growth		 8.31% 2.34% 9.93% 5.82% 5.75% 8.03% 4.50% -0.05% 2.61% 2.93% 2.55%
EBITDA Q/Q Growth		 7.13% -54.19% 46.37% 16.33% -1.34% 3.87% 58.75% -51.78% 16.84% 20.66% -3.31%
EBIT Q/Q Growth		 8.13% -503.89% 632.99% 169.50% -7.60% -0.61% 83.06% -121.83% 9.26% 6.90% -0.41%
NOPAT Q/Q Growth		 10.71% -2,354.36% 632.99% 169.79% -55.94% 167.80% 18.70% 12.81% 8.79% 6.76% 0.19%
Net Income Q/Q Growth		 20.17% -776.00% -350.95% 96.58% -61.39% 288.08% 184.30% -117.09% 11.68% 8.68% -1.28%
EPS Q/Q Growth		 0.00% -500.00% -66.67% 61.11% -22.22% 300.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 18.73% 21.59% -9.91% 49.85% 27.62% -34.10% 225.21% -2,677.86% 19.60% 91.66% -53.20%
Free Cash Flow Firm Q/Q Growth		 24.10% -5,078.49% 103.03% 0.00% -979.07% 112.56% 2.60% 3.75% 18.63% 25.01% -32.33%
Invested Capital Q/Q Growth		 6.44% 656.22% -0.10% 1.60% 41.02% 3.31% 2.48% -0.08% -0.79% -1.67% -0.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 46.76% 43.84% 42.32% 42.44% 45.99% 48.15% 41.83% 38.62% 36.86% 41.34% 43.92%
EBITDA Margin		 9.17% 3.51% 12.45% 10.79% 11.68% 9.55% 8.58% 9.52% -16.79% -5.35% -2.58%
Operating Margin		 2.55% -5.65% 0.93% 1.21% 3.63% 3.18% -3.15% -24.52% -30.92% -18.21% -13.94%
EBIT Margin		 2.61% -3.64% 0.93% 1.20% 3.63% 2.05% -0.48% -2.06% -30.96% -18.10% -14.00%
Profit (Net Income) Margin		 1.30% -2.54% -2.65% -0.16% 0.95% 1.96% 0.94% -1.72% -28.30% -14.87% -11.92%
Tax Burden Percent		 87.82% 56.47% 78.31% 14.94% 69.04% 219.64% -29.68% 55.37% 90.53% 90.60% 97.58%
Interest Burden Percent		 56.68% 123.49% -363.94% -91.70% 38.03% 43.52% 659.60% 150.86% 100.95% 90.67% 87.23%
Effective Tax Rate		 12.18% 0.00% 0.00% 0.00% 30.96% -119.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 6.24% -2.46% 0.53% 0.70% 1.94% 6.74% -2.02% -10.00% -9.94% -6.98% -6.08%
ROIC Less NNEP Spread (ROIC-NNEP)		 14.53% 9.94% -10.27% -1.90% -2.60% -198.82% -13.97% -116.38% -69.21% -18.38% -16.36%
Return on Net Nonoperating Assets (RNNOA)		 -3.48% 0.76% -3.43% -0.91% -0.94% -4.80% 2.72% 9.08% -3.76% -2.09% -2.46%
Return on Equity (ROE)		 2.76% -1.70% -2.89% -0.20% 1.01% 1.93% 0.69% -0.93% -13.70% -9.07% -8.54%
Cash Return on Invested Capital (CROIC)		 -19.25% -158.63% 2.59% -5.16% -31.53% 3.30% -23.80% -80.86% -7.23% -4.13% -5.33%
Operating Return on Assets (OROA)		 3.76% -1.68% 0.63% 0.85% 2.37% 1.38% -0.25% -0.70% -8.74% -6.26% -5.57%
Return on Assets (ROA)		 1.87% -1.17% -1.78% -0.12% 0.62% 1.32% 0.49% -0.58% -7.99% -5.14% -4.74%
Return on Common Equity (ROCE)		 2.76% -1.54% -2.54% -0.17% 0.94% 1.93% 0.69% -0.93% -13.70% -9.07% -8.54%
Return on Equity Simple (ROE_SIMPLE)		 1.87% -1.21% -3.75% -0.23% 0.82% 1.58% 0.60% -0.75% -14.45% -9.34% -8.72%
Net Operating Profit after Tax (NOPAT)		 1.95 -3.94 1.51 2.03 6.93 29 -9.79 -83 -110 -75 -64
NOPAT Margin		 2.24% -3.95% 0.65% 0.85% 2.50% 6.99% -2.20% -17.16% -21.65% -12.75% -9.76%
Net Nonoperating Expense Percent (NNEP)		 -8.29% -12.39% 10.81% 2.61% 4.55% 205.56% 11.94% 106.37% 59.28% 11.39% 10.28%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -7.20% -5.10% -4.47%
Cost of Revenue to Revenue		 53.24% 56.16% 57.68% 57.56% 54.01% 51.85% 58.17% 61.38% 63.14% 58.66% 56.08%
SG&A Expenses to Revenue		 27.34% 33.70% 27.58% 29.29% 30.65% 31.31% 32.35% 45.70% 47.74% 41.09% 39.32%
R&D to Revenue		 3.09% 4.21% 2.01% 1.51% 1.08% 2.08% 1.85% 4.52% 5.95% 4.62% 4.72%
Operating Expenses to Revenue		 44.21% 49.49% 41.39% 41.23% 42.36% 44.96% 44.97% 63.14% 67.79% 59.55% 57.86%
Earnings before Interest and Taxes (EBIT)		 2.27 -3.64 2.16 2.89 10 8.38 -2.13 -9.99 -158 -107 -92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 7.98 3.51 29 26 32 39 38 46 -86 -32 -17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.14 2.27 4.11 4.14 3.66 6.02 8.61 3.79 1.17 2.19 2.34
Price to Tangible Book Value (P/TBV)		 4.70 0.00 0.00 0.00 0.00 16.76 16.49 30.26 17.42 45.19 53.03
Price to Revenue (P/Rev)		 2.87 4.76 2.90 2.97 4.24 7.47 13.45 8.67 2.29 3.49 3.20
Price to Earnings (P/E)		 220.92 0.00 0.00 0.00 192.66 381.45 1,432.85 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.45% 0.00% 0.00% 0.00% 0.52% 0.26% 0.07% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.39 1.93 2.82 2.82 3.05 6.91 10.85 3.92 1.15 2.05 2.15
Enterprise Value to Revenue (EV/Rev)		 2.58 5.53 3.41 3.49 4.59 7.28 13.10 9.12 2.48 3.69 3.44
Enterprise Value to EBITDA (EV/EBITDA)		 28.18 157.26 27.35 32.32 39.26 76.28 152.71 95.80 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 98.89 0.00 366.30 289.84 126.23 355.51 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 115.45 0.00 523.28 412.35 183.10 104.24 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 23.80 86.27 36.75 46.44 28.34 127.42 3,986.40 0.00 0.00 0.00 323.17
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 107.55 0.00 0.00 212.99 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.14 0.30 0.57 0.52 0.33 0.19 0.24 0.48 0.54 0.57 0.60
Long-Term Debt to Equity		 0.09 0.24 0.52 0.47 0.31 0.18 0.24 0.48 0.54 0.57 0.38
Financial Leverage		 -0.24 0.08 0.33 0.48 0.36 0.02 -0.19 -0.08 0.05 0.11 0.15
Leverage Ratio		 1.47 1.45 1.62 1.74 1.62 1.47 1.41 1.59 1.71 1.76 1.80
Compound Leverage Factor		 0.84 1.79 -5.90 -1.60 0.62 0.64 9.32 2.39 1.73 1.60 1.57
Debt to Total Capital		 12.31% 23.06% 36.26% 34.01% 24.86% 16.03% 19.49% 32.45% 34.91% 36.37% 37.49%
Short-Term Debt to Total Capital		 4.68% 4.52% 2.98% 2.90% 1.85% 0.83% 0.00% 0.00% 0.00% 0.00% 13.91%
Long-Term Debt to Total Capital		 7.63% 18.54% 33.28% 31.11% 23.01% 15.20% 19.49% 32.45% 34.91% 36.37% 23.58%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 9.24% 7.81% 10.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 87.69% 67.70% 55.92% 55.47% 75.14% 83.98% 80.51% 67.55% 65.09% 63.63% 62.51%
Debt to EBITDA		 1.06 20.35 3.68 4.07 3.28 2.48 4.41 11.55 -6.26 -17.01 -31.79
Net Debt to EBITDA		 -3.16 13.68 3.24 3.57 2.98 -1.95 -4.14 4.68 -1.14 -3.89 -9.06
Long-Term Debt to EBITDA		 0.66 16.36 3.38 3.72 3.04 2.35 4.41 11.55 -6.26 -17.01 -19.99
Debt to NOPAT		 4.35 -18.10 70.38 51.90 15.29 3.39 -17.16 -6.41 -4.85 -7.14 -8.39
Net Debt to NOPAT		 -12.94 -12.16 62.08 45.59 13.88 -2.67 16.10 -2.59 -0.88 -1.63 -2.39
Long-Term Debt to NOPAT		 2.70 -14.55 64.59 47.47 14.16 3.21 -17.16 -6.41 -4.85 -7.14 -5.28
Altman Z-Score		 8.73 2.82 3.32 3.72 4.47 10.04 13.09 3.92 1.16 1.97 1.88
Noncontrolling Interest Sharing Ratio		 0.00% 9.58% 12.12% 14.19% 6.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.02 2.06 2.07 2.35 1.70 4.55 6.13 7.81 6.73 6.20 1.98
Quick Ratio		 3.70 1.81 1.79 2.01 1.42 4.18 5.51 4.92 6.20 5.67 1.78
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.01 -255 7.34 -15 -113 14 -115 -672 -80 -45 -57
Operating Cash Flow to CapEx		 250.53% 288.62% 284.99% 131.75% 312.97% 116.68% 5.02% -41.66% -351.16% -6.79% 17.10%
Free Cash Flow to Firm to Interest Expense		 -6.10 -298.38 0.73 -2.69 -18.06 2.96 -9.66 -81.74 -10.60 -6.46 -8.55
Operating Cash Flow to Interest Expense		 9.59 7.49 2.15 3.26 7.19 4.94 0.12 -3.25 -8.71 -0.28 1.06
Operating Cash Flow Less CapEx to Interest Expense		 5.76 4.89 1.39 0.78 4.89 0.71 -2.32 -11.05 -11.18 -4.45 -5.14
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.44 0.46 0.67 0.71 0.65 0.67 0.52 0.34 0.28 0.35 0.40
Accounts Receivable Turnover		 4.45 2.88 4.44 4.14 4.03 4.78 4.42 4.42 4.40 4.72 4.69
Inventory Turnover		 18.86 14.51 23.54 20.15 18.54 18.39 11.77 11.23 13.50 14.33 14.56
Fixed Asset Turnover		 7.03 4.02 6.76 6.81 5.68 6.54 5.92 4.96 4.81 6.08 7.10
Accounts Payable Turnover		 8.85 5.98 9.14 10.16 10.59 11.35 11.61 13.86 16.75 16.99 17.67
Days Sales Outstanding (DSO)		 82.01 126.94 82.24 88.07 90.57 76.41 82.57 82.51 83.01 77.41 77.85
Days Inventory Outstanding (DIO)		 19.36 25.15 15.51 18.11 19.69 19.85 31.01 32.49 27.03 25.47 25.08
Days Payable Outstanding (DPO)		 41.22 61.08 39.92 35.94 34.47 32.15 31.43 26.33 21.79 21.48 20.66
Cash Conversion Cycle (CCC)		 60.15 91.01 57.82 70.25 75.80 64.10 82.14 88.67 88.25 81.40 82.26
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 35 286 280 297 417 431 537 1,125 1,095 1,065 1,057
Invested Capital Turnover		 2.79 0.62 0.82 0.83 0.78 0.96 0.92 0.58 0.46 0.55 0.62
Increase / (Decrease) in Invested Capital		 7.96 251 -5.83 17 119 15 105 589 -30 -31 -7.93
Enterprise Value (EV)		 225 552 789 838 1,269 2,978 5,820 4,417 1,264 2,185 2,270
Market Capitalization		 250 475 673 712 1,173 3,054 5,978 4,201 1,167 2,062 2,115
Book Value per Share		 $1.01 $3.47 $2.09 $2.14 $3.45 $4.86 $6.25 $9.00 $7.90 $7.39 $7.03
Tangible Book Value per Share		 $0.89 ($0.41) ($0.77) ($0.61) ($0.19) $1.74 $3.27 $1.13 $0.53 $0.36 $0.31
Total Capital		 69 309 293 310 426 604 862 1,641 1,533 1,480 1,443
Total Debt		 8.48 71 106 105 106 97 168 532 535 538 541
Total Long-Term Debt		 5.26 57 97 96 98 92 168 532 535 538 340
Net Debt		 -25 48 94 93 96 -76 -158 216 97 123 154
Capital Expenditures (CapEx)		 3.77 2.22 7.54 14 14 20 29 64 19 29 41
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 14 33 37 46 41 59 79 277 77 85 109
Debt-free Net Working Capital (DFNWC)		 47 56 49 58 51 232 376 594 515 501 496
Net Working Capital (NWC)		 44 42 41 49 43 227 376 594 515 501 295
Net Nonoperating Expense (NNE)		 0.82 -1.41 7.65 2.43 4.29 21 -14 -75 34 13 14
Net Nonoperating Obligations (NNO)		 -25 48 94 93 96 -76 -158 17 97 123 154
Total Depreciation and Amortization (D&A)		 5.71 7.14 27 23 22 31 40 56 72 75 75
Debt-free, Cash-free Net Working Capital to Revenue		 15.68% 32.95% 15.93% 18.97% 14.74% 14.39% 17.84% 57.29% 15.18% 14.42% 16.46%
Debt-free Net Working Capital to Revenue		 54.37% 56.42% 21.33% 24.31% 18.29% 56.71% 84.50% 122.70% 101.10% 84.60% 75.02%
Net Working Capital to Revenue		 50.67% 42.39% 17.56% 20.56% 15.45% 55.48% 84.50% 122.70% 101.10% 84.60% 44.63%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.02 $0.00 ($0.39) $0.00 $0.07 $0.08 $0.04 ($0.07) $0.00 $0.00 ($0.62)
Adjusted Weighted Average Basic Shares Outstanding		 53.48M 0.00 77.54M 79.43M 85.62M 100.47M 108.58M 119.96M 124.22M 125.50M 126.66M
Adjusted Diluted Earnings per Share		 $0.02 $0.00 ($0.39) $0.00 $0.07 $0.08 $0.04 ($0.07) $0.00 $0.00 ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding		 56.02M 0.00 77.54M 79.43M 91.57M 103.62M 111.79M 119.96M 124.22M 125.50M 126.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.26M 0.00 78.82M 80.51M 94.57M 104.83M 116.94M 124.03M 127.46M 127.61M 128.46M
Normalized Net Operating Profit after Tax (NOPAT)		 1.95 -3.94 3.93 2.03 6.93 9.10 -9.79 -83 -107 -68 -60
Normalized NOPAT Margin		 2.24% -3.95% 1.70% 0.85% 2.50% 2.23% -2.20% -17.16% -21.03% -11.43% -9.05%
Pre Tax Income Margin		 1.48% -4.50% -3.38% -1.10% 1.38% 0.89% -3.16% -3.11% -31.26% -16.41% -12.21%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 2.31 -4.26 0.22 0.52 1.61 1.77 -0.18 -1.22 -20.82 -15.50 -13.98
NOPAT to Interest Expense		 1.98 -4.62 0.15 0.37 1.11 6.04 -0.82 -10.11 -14.55 -10.92 -9.74
EBIT Less CapEx to Interest Expense		 -1.52 -6.85 -0.54 -1.95 -0.68 -2.46 -2.62 -9.02 -23.30 -19.67 -20.18
NOPAT Less CapEx to Interest Expense		 -1.85 -7.21 -0.60 -2.10 -1.18 1.80 -3.26 -17.92 -17.03 -15.08 -15.95
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for NeoGenomics

This table displays calculated financial ratios and metrics derived from NeoGenomics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 6.13% 10.32% 17.11% 17.47% 17.99% 12.15% 13.86% 11.97% 10.44% 10.57% 7.55%
EBITDA Growth		 -371.48% 69.50% 51.44% 54.48% 74.49% 108.32% 28.86% 69.48% 60.18% -86.10% 21.46%
EBIT Growth		 -80.51% 37.91% 32.15% 27.28% 38.48% 30.07% 12.38% 24.76% 14.04% -2.07% 9.96%
NOPAT Growth		 0.51% 36.53% 32.59% 24.70% 38.76% 29.60% 12.85% 26.60% 12.39% 0.93% 8.97%
Net Income Growth		 -81.11% 45.67% 37.67% 31.08% 49.76% 36.85% 12.13% 23.38% 4.41% -6.97% 4.21%
EPS Growth		 -76.47% 0.00% 37.50% 0.00% 50.00% 0.00% 16.00% 0.00% 6.67% 0.00% 4.76%
Operating Cash Flow Growth		 -109.50% 81.37% 56.29% 90.89% 66.22% 582.61% -104.18% 997.42% 268.20% -44.89% 2.27%
Free Cash Flow Firm Growth		 99.14% 101.87% 101.55% 121.98% 183.01% 54.36% -165.60% -91.88% 56.74% -127.81% -121.80%
Invested Capital Growth		 -1.98% -2.67% -3.03% -2.51% -1.94% -2.81% -1.38% -1.47% -2.02% -0.74% -0.51%
Revenue Q/Q Growth		 2.97% 7.71% -1.07% 7.07% 3.43% 2.37% 0.44% 5.29% 2.02% 2.49% -2.31%
EBITDA Q/Q Growth		 4.79% 64.32% -118.85% 38.78% 46.63% 111.64% -1,970.14% 73.74% 30.36% 104.06% -10,664.77%
EBIT Q/Q Growth		 1.55% 33.18% -33.36% 17.12% 16.71% 24.05% -67.10% 28.83% 4.84% 9.81% -47.41%
NOPAT Q/Q Growth		 0.48% 33.22% -32.94% 14.77% 19.06% 23.23% -64.57% 28.22% 3.39% 13.19% -51.21%
Net Income Q/Q Growth		 -4.39% 38.44% -35.74% 20.99% 23.90% 22.63% -88.89% 31.11% 5.06% 13.42% -69.17%
EPS Q/Q Growth		 -7.14% 40.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 4.26% 77.35% -244.42% 87.80% -255.10% 423.52% -245.72% 153.61% -33.44% 5.99% -358.44%
Free Cash Flow Firm Q/Q Growth		 82.90% 313.85% -16.61% -27.95% -35.40% 297.68% -135.44% 108.92% 1,146.96% -170.55% -182.67%
Invested Capital Q/Q Growth		 -0.67% -0.79% -0.25% -0.82% -0.09% -1.67% 1.22% -0.91% -0.65% -0.39% 1.46%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 37.97% 40.97% 39.95% 40.77% 41.01% 43.45% 41.90% 44.07% 44.62% 44.92% 43.59%
EBITDA Margin		 -16.55% -5.48% -12.13% -6.93% -3.58% 0.41% -7.58% -1.89% -1.29% 0.05% -5.53%
Operating Margin		 -30.68% -19.02% -25.56% -20.35% -15.92% -11.94% -19.56% -13.34% -12.63% -10.70% -16.56%
EBIT Margin		 -30.66% -19.02% -25.64% -19.85% -15.99% -11.86% -19.73% -13.34% -12.44% -10.95% -16.52%
Profit (Net Income) Margin		 -28.62% -16.36% -22.44% -16.56% -12.19% -9.21% -17.32% -11.33% -10.55% -8.91% -15.43%
Tax Burden Percent		 93.00% 88.89% 91.33% 91.33% 86.32% 93.72% 97.76% 98.03% 99.16% 95.01% 101.04%
Interest Burden Percent		 100.35% 96.74% 95.83% 91.35% 88.31% 82.85% 89.79% 86.67% 85.48% 85.64% 92.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -9.57% -6.11% -8.54% -7.16% -5.86% -4.58% -7.71% -5.45% -5.31% -4.66% -7.25%
ROIC Less NNEP Spread (ROIC-NNEP)		 -32.51% -13.49% -15.89% -10.64% -7.26% -5.78% -11.87% -7.81% -7.30% -6.43% -11.07%
Return on Net Nonoperating Assets (RNNOA)		 -1.21% -0.73% -1.32% -1.04% -0.84% -0.66% -1.70% -1.16% -1.13% -0.97% -2.06%
Return on Equity (ROE)		 -10.78% -6.84% -9.86% -8.20% -6.70% -5.24% -9.41% -6.62% -6.45% -5.63% -9.32%
Cash Return on Invested Capital (CROIC)		 -8.85% -7.23% -5.79% -5.81% -5.44% -4.13% -5.27% -4.72% -3.99% -5.33% -5.31%
Operating Return on Assets (OROA)		 -8.32% -5.37% -7.68% -6.28% -5.35% -4.10% -7.20% -5.02% -4.83% -4.36% -6.85%
Return on Assets (ROA)		 -7.76% -4.62% -6.72% -5.24% -4.08% -3.19% -6.32% -4.27% -4.09% -3.55% -6.40%
Return on Common Equity (ROCE)		 -10.78% -6.84% -9.86% -8.20% -6.70% -5.24% -9.41% -6.62% -6.45% -5.63% -9.32%
Return on Equity Simple (ROE_SIMPLE)		 -16.12% 0.00% -12.89% -11.99% -10.17% 0.00% -9.12% -8.58% -8.56% 0.00% -8.73%
Net Operating Profit after Tax (NOPAT)		 -28 -18 -25 -21 -17 -13 -21 -15 -15 -13 -19
NOPAT Margin		 -21.48% -13.31% -17.89% -14.24% -11.15% -8.36% -13.69% -9.34% -8.84% -7.49% -11.59%
Net Nonoperating Expense Percent (NNEP)		 22.95% 7.37% 7.35% 3.49% 1.40% 1.20% 4.16% 2.35% 1.99% 1.76% 3.82%
Return On Investment Capital (ROIC_SIMPLE)		 - -1.20% - - - -0.88% - - - -0.89% -1.36%
Cost of Revenue to Revenue		 62.03% 59.03% 60.05% 59.23% 58.99% 56.55% 58.10% 55.93% 55.38% 55.08% 56.41%
SG&A Expenses to Revenue		 49.92% 39.56% 44.85% 41.05% 40.46% 38.42% 42.11% 38.50% 39.90% 37.00% 40.59%
R&D to Revenue		 5.68% 4.81% 5.39% 5.11% 3.48% 4.58% 4.88% 4.79% 4.58% 4.63% 6.06%
Operating Expenses to Revenue		 68.65% 59.99% 65.51% 61.11% 56.93% 55.39% 61.47% 57.41% 57.25% 55.62% 60.15%
Earnings before Interest and Taxes (EBIT)		 -39 -26 -35 -29 -24 -18 -31 -22 -21 -19 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -7.60 -17 -10 -5.44 0.63 -12 -3.11 -2.17 0.09 -9.30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.07 1.17 2.28 2.14 1.66 2.19 2.17 1.93 2.08 2.34 1.37
Price to Tangible Book Value (P/TBV)		 14.76 17.42 42.49 47.98 36.70 45.19 55.85 48.25 50.54 53.03 35.66
Price to Revenue (P/Rev)		 2.18 2.29 4.19 3.72 2.73 3.49 3.28 2.82 2.93 3.20 1.81
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.06 1.15 2.14 2.01 1.57 2.05 2.00 1.80 1.93 2.15 1.31
Enterprise Value to Revenue (EV/Rev)		 2.36 2.48 4.41 3.95 2.96 3.69 3.53 3.06 3.17 3.44 2.09
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7,284.70 136.13 323.17 184.32
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.53 0.54 0.55 0.56 0.57 0.57 0.58 0.59 0.60 0.60 0.61
Long-Term Debt to Equity		 0.53 0.54 0.55 0.56 0.57 0.57 0.58 0.37 0.37 0.38 0.38
Financial Leverage		 0.04 0.05 0.08 0.10 0.12 0.11 0.14 0.15 0.16 0.15 0.19
Leverage Ratio		 1.70 1.71 1.73 1.74 1.75 1.76 1.76 1.78 1.79 1.80 1.79
Compound Leverage Factor		 1.71 1.66 1.65 1.59 1.55 1.46 1.58 1.55 1.53 1.54 1.65
Debt to Total Capital		 34.54% 34.91% 35.49% 35.95% 36.20% 36.37% 36.85% 37.08% 37.30% 37.49% 37.89%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.75% 13.84% 13.91% 14.06%
Long-Term Debt to Total Capital		 34.54% 34.91% 35.49% 35.95% 36.20% 36.37% 36.85% 23.33% 23.47% 23.58% 23.82%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 65.46% 65.09% 64.51% 64.05% 63.80% 63.63% 63.15% 62.92% 62.70% 62.51% 62.11%
Debt to EBITDA		 -5.20 -6.26 -7.89 -9.63 -13.48 -17.01 -20.09 -27.32 -32.79 -31.79 -37.41
Net Debt to EBITDA		 -0.89 -1.14 -1.74 -2.29 -3.39 -3.89 -5.74 -7.69 -9.26 -9.06 -12.69
Long-Term Debt to EBITDA		 -5.20 -6.26 -7.89 -9.63 -13.48 -17.01 -20.09 -17.19 -20.63 -19.99 -23.53
Debt to NOPAT		 -4.42 -4.85 -5.44 -5.86 -6.65 -7.14 -7.46 -8.09 -8.37 -8.39 -8.66
Net Debt to NOPAT		 -0.75 -0.88 -1.20 -1.39 -1.67 -1.63 -2.13 -2.28 -2.36 -2.39 -2.94
Long-Term Debt to NOPAT		 -4.42 -4.85 -5.44 -5.86 -6.65 -7.14 -7.46 -5.09 -5.26 -5.28 -5.45
Altman Z-Score		 1.33 1.41 2.25 2.10 1.74 2.14 2.12 1.76 1.85 2.03 1.30
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.10 6.73 6.75 6.16 6.32 6.20 7.48 2.01 1.99 1.98 2.05
Quick Ratio		 6.54 6.20 6.20 5.64 5.76 5.67 6.85 1.84 1.82 1.78 1.82
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.40 12 9.63 6.94 4.48 18 -6.32 0.56 7.02 -4.96 -14
Operating Cash Flow to CapEx		 -207.45% -81.27% -127.85% -20.66% -128.61% 252.01% -464.01% 106.22% 85.62% 84.49% -562.82%
Free Cash Flow to Firm to Interest Expense		 -38.84 2.21 5.48 3.89 2.66 10.60 -3.75 0.34 4.28 -3.05 -8.66
Operating Cash Flow to Interest Expense		 -117.06 -0.71 -7.22 -0.87 -3.26 10.58 -15.38 8.34 5.63 6.03 -15.65
Operating Cash Flow Less CapEx to Interest Expense		 -173.50 -1.58 -12.87 -5.07 -5.80 6.38 -18.69 0.49 -0.95 -1.11 -18.43
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.27 0.28 0.30 0.32 0.33 0.35 0.36 0.38 0.39 0.40 0.41
Accounts Receivable Turnover		 4.58 4.40 4.61 4.66 4.70 4.72 4.71 4.62 4.54 4.69 4.61
Inventory Turnover		 14.04 13.50 13.48 14.15 14.25 14.33 15.88 14.97 14.99 14.56 14.95
Fixed Asset Turnover		 4.64 4.81 5.00 5.22 5.71 6.08 6.40 6.54 6.87 7.10 7.58
Accounts Payable Turnover		 15.17 16.75 15.06 19.06 22.34 16.99 17.32 20.54 21.82 17.67 21.68
Days Sales Outstanding (DSO)		 79.71 83.01 79.11 78.31 77.67 77.41 77.44 79.02 80.49 77.85 79.12
Days Inventory Outstanding (DIO)		 25.99 27.03 27.08 25.79 25.61 25.47 22.98 24.39 24.34 25.08 24.41
Days Payable Outstanding (DPO)		 24.06 21.79 24.23 19.15 16.34 21.48 21.08 17.77 16.73 20.66 16.84
Cash Conversion Cycle (CCC)		 81.64 88.25 81.96 84.95 86.95 81.40 79.34 85.63 88.10 82.26 86.69
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,104 1,095 1,093 1,084 1,083 1,065 1,078 1,068 1,061 1,057 1,072
Invested Capital Turnover		 0.45 0.46 0.48 0.50 0.53 0.55 0.56 0.58 0.60 0.62 0.63
Increase / (Decrease) in Invested Capital		 -22 -30 -34 -28 -21 -31 -15 -16 -22 -7.93 -5.47
Enterprise Value (EV)		 1,174 1,264 2,337 2,178 1,704 2,185 2,158 1,923 2,043 2,270 1,403
Market Capitalization		 1,083 1,167 2,219 2,050 1,569 2,062 2,004 1,771 1,890 2,115 1,219
Book Value per Share		 $8.05 $7.90 $7.65 $7.50 $7.43 $7.39 $7.32 $7.17 $7.09 $7.03 $6.91
Tangible Book Value per Share		 $0.58 $0.53 $0.41 $0.34 $0.34 $0.36 $0.28 $0.29 $0.29 $0.31 $0.27
Total Capital		 1,548 1,533 1,510 1,493 1,485 1,480 1,462 1,456 1,449 1,443 1,430
Total Debt		 535 535 536 537 537 538 539 540 540 541 542
Total Long-Term Debt		 535 535 536 537 537 538 539 340 340 340 341
Net Debt		 91 97 118 127 135 123 154 152 153 154 184
Capital Expenditures (CapEx)		 7.84 4.53 9.93 7.49 4.27 7.06 5.59 13 11 12 4.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 75 77 80 81 92 85 112 106 106 109 137
Debt-free Net Working Capital (DFNWC)		 518 515 498 490 494 501 497 494 494 496 495
Net Working Capital (NWC)		 518 515 498 490 494 501 497 294 294 295 294
Net Nonoperating Expense (NNE)		 9.20 4.22 6.24 3.41 1.58 1.32 5.66 3.28 2.86 2.44 6.45
Net Nonoperating Obligations (NNO)		 91 97 118 127 135 123 154 152 153 154 184
Total Depreciation and Amortization (D&A)		 18 19 19 19 19 19 19 19 19 19 18
Debt-free, Cash-free Net Working Capital to Revenue		 15.06% 15.18% 15.19% 14.60% 15.96% 14.42% 18.40% 16.95% 16.53% 16.46% 20.42%
Debt-free Net Working Capital to Revenue		 104.35% 101.10% 94.08% 88.81% 85.95% 84.60% 81.42% 78.68% 76.73% 75.02% 73.68%
Net Working Capital to Revenue		 104.35% 101.10% 94.08% 88.81% 85.95% 84.60% 81.42% 46.84% 45.62% 44.63% 43.76%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.30) ($0.18) ($0.25) ($0.19) ($0.15) $0.00 ($0.21) $0.00 ($0.14) $0.00 ($0.20)
Adjusted Weighted Average Basic Shares Outstanding		 124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M 127.38M
Adjusted Diluted Earnings per Share		 ($0.30) ($0.18) ($0.25) ($0.19) ($0.15) $0.00 ($0.21) $0.00 ($0.14) $0.00 ($0.20)
Adjusted Weighted Average Diluted Shares Outstanding		 124.43M 124.22M 125.03M 125.36M 125.69M 125.50M 126.11M 126.41M 126.95M 126.66M 127.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 126.30M 127.46M 127.58M 127.55M 127.47M 127.61M 127.71M 128.16M 128.36M 128.46M 128.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -15 -21 -19 -15 -12 -20 -14 -14 -12 -19
Normalized NOPAT Margin		 -21.48% -11.04% -15.50% -12.78% -10.17% -7.82% -12.62% -8.68% -8.42% -6.79% -11.59%
Pre Tax Income Margin		 -30.77% -18.40% -24.57% -18.13% -14.12% -9.83% -17.72% -11.56% -10.64% -9.38% -15.27%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -284.06 -5.06 -20.03 -16.35 -14.42 -10.98 -18.30 -13.17 -12.72 -11.60 -17.16
NOPAT to Interest Expense		 -198.97 -3.54 -13.97 -11.73 -10.05 -7.73 -12.70 -9.22 -9.04 -7.93 -12.04
EBIT Less CapEx to Interest Expense		 -340.50 -5.93 -25.68 -20.55 -16.95 -15.17 -21.61 -21.02 -19.29 -18.74 -19.94
NOPAT Less CapEx to Interest Expense		 -255.40 -4.41 -19.62 -15.93 -12.59 -11.93 -16.01 -17.07 -15.61 -15.07 -14.82
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About NeoGenomics' Financials

When does NeoGenomics's financial year end?

According to the most recent income statement we have on file, NeoGenomics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has NeoGenomics' net income changed over the last 10 years?

NeoGenomics' net income appears to be on an upward trend, with a most recent value of -$78.73 million in 2024, falling from $1.13 million in 2014. The previous period was -$87.97 million in 2023. Find out what analysts predict for NeoGenomics in the coming months.

What is NeoGenomics's operating income?
NeoGenomics's total operating income in 2024 was -$92.11 million, based on the following breakdown:
  • Total Gross Profit: $290.10 million
  • Total Operating Expenses: $382.21 million
How has NeoGenomics revenue changed over the last 10 years?

Over the last 10 years, NeoGenomics' total revenue changed from $87.07 million in 2014 to $660.57 million in 2024, a change of 658.7%.

How much debt does NeoGenomics have?

NeoGenomics' total liabilities were at $735.70 million at the end of 2024, a 0.5% decrease from 2023, and a 3,453.9% increase since 2014.

How much cash does NeoGenomics have?

In the past 10 years, NeoGenomics' cash and equivalents has ranged from $9.81 million in 2018 to $367.01 million in 2024, and is currently $367.01 million as of their latest financial filing in 2024.

How has NeoGenomics' book value per share changed over the last 10 years?

Over the last 10 years, NeoGenomics' book value per share changed from 1.01 in 2014 to 7.03 in 2024, a change of 597.9%.


Related Companies

This page (NASDAQ:NEO) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...
Crypto 101 Media | Sponsored
Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...
Weiss Ratings | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored